NEW YORK (GenomeWeb News) – Nuclea Biotechnologies this week announced Immuno-Biological Laboratories will be the primary US distributor of Nuclea's HER-2/neu kits.
Nuclea and IBL also will coordinate joint marketing efforts for the serum HER-2/neu kits as part of the deal.
The microtiter-based test measures the level of HER-2/neu in serum and is used to monitor metastatic breast cancer. Based in Minneapolis, IBL distributes diagnostic assays for autoimmunity, endocrinology, infectious disease, oncology, and neuroscience. It also offers laboratory services.
Financial and other terms of the agreement were not disclosed.
Earlier this week, Nuclea announced an agreement with Enzo Clinical Labs to market the HER-2/neu test.